February 12, 2008

Dear Healthcare Professional:

Critical Therapeutics, Inc. announced the commercial launch of ZYFLO CR™ (zileuton) extended-release tablets in September 2007. Since this time, prescriptions for ZYFLO CR have consistently grown, and as expected, ZYFLO® (zileuton tablets), the four-times-per-day immediate-release formulation of zileuton (hereby referred to as ZYFLO IR), utilization has declined.

Critical Therapeutics has notified the FDA about discontinuing ZYFLO IR. ZYFLO IR will remain available through pharmacies and wholesalers until supplies are exhausted, which we expect to be on or around March 1, 2008. After Critical Therapeutics' pharmacy and wholesaler supplies of ZYFLO IR are exhausted, no additional product will be available.

If you are aware of a patient receiving ZYFLO IR, please notify the prescribing healthcare provider (if someone other than yourself) and the patient regarding this information. The prescribing healthcare provider should initiate steps to convert ZYFLO IR-treated patients to ZYFLO CR as soon as possible to ensure patients experience no disruption in their use of zileuton. There is more than adequate supply of ZYFLO CR available in the market and we are confident the discontinuation of ZYFLO IR will proceed smoothly. ZYFLO CR comes at no additional cost compared with ZYFLO IR.

Should you or your colleagues have any questions or concerns, our Medical Information department may be contacted at 800.918.8899.

Sincerely,



Frank E. Thomas
President, CEO and Director

ZYFLO CR is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. ZYFLO CR is not indicated for use in the reversal of bronchospasm in acute asthma attacks. Therapy with ZYFLO CR can be continued during acute exacerbations of asthma.

The recommended dose of ZYFLO CR is two 600 mg extended-release tablets twice daily, within one hour after morning and evening meals, for a total daily dose of 2400 mg.

ZYFLO CR and ZYFLO are contraindicated in patients with active liver disease or transaminase elevations greater than or equal to three times the upper limit of normal. Liver enzymes should be monitored prior to administering ZYFLO CR and repeated on a regular basis while patients are on the medication.

Please see enclosed full prescribing information for ZYFLO CR.

ZYFLO CR™
(zileuton) extended-release tablets, 600 mg